Becton Dickinson holds a cautious analyst view, shares trade below recent targets
23.06.2026 - 21:29:29 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 21:22.
Becton Dickinson (US0718131099) remains in focus on the NYSE as analysts reassess large-cap medtech valuations. Bank of America recently trimmed its price target and reiterated a Neutral stance, while the stock trades materially below its 2023 all-time high.
What Bank of America says
On 2026-06-12, Bank of America lowered its Becton Dickinson price target from 177 to 170 US dollars and kept a Neutral rating, citing a softer utilization environment and inflation risks for 2027 in the wider medtech sector. A detailed summary of the BofA note is carried by Yahoo Finance.
According to MarketBeat, 16 Wall Street analysts currently cover Becton Dickinson, with 7 Buy, 8 Hold and 1 Sell recommendation, giving the stock an overall "Hold" consensus rating. MarketBeat’s consensus data put the average target price at 140.37 dollars as of 2026-06-22.
Consensus and NYSE trading picture
Becton Dickinson shares are listed on the NYSE under the ticker BDX and are part of the S&P 500 healthcare cohort alongside peers such as Medtronic and Abbott Laboratories. MarketBeat shows the latest consensus rating unchanged at Hold, reflecting the split analyst view between growth prospects and margin pressure in medtech. Current NYSE trading headlines compiled by MarketBeat highlight a 2.78 percent intraday move to 144.62 dollars at 15:04 Eastern on 2026-06-22.
Historical data from StockScan indicates that Becton Dickinson closed at 145.43 dollars on 2026-06-23, around 49 percent below its all-time high of 287.32 dollars reached on 2023-07-24, underscoring the de-rating in the sector. StockScan’s price history provides the adjusted series including splits and dividends.
All news and analysis on the Becton Dickinson shares
Background, corporate releases and further price data on Becton Dickinson are available in the dedicated topic section and on the company’s Investor Relations site.
The product behind the stock
Becton Dickinson generates a large share of its revenue from medical-surgical products such as syringes, needles and infusion therapy systems, including the well-known BD Venflon peripheral IV catheter line used in hospitals worldwide for vascular access procedures.
Where the stock trades today
The Becton Dickinson shares (US0718131099) last closed on the NYSE at 145.43 US dollars on 2026-06-23, according to StockScan, with the price data adjusted for stock splits and dividends.
Key data on the Becton Dickinson shares
- Company: Becton, Dickinson and Company
- ISIN: US0718131099
- WKN: 857675
- Ticker: BDX
- Trading venue: NYSE
- Price (as of 2026-06-23, 20:00): 145.43 USD
- Market cap: 42.5 billion USD (as of 2026-06-23)
- Sector / industry: Health Care – Medical Devices
- Index membership: S&P 500
- Next earnings date: 2026-08-01
This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any securities. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.
